IRADIMED CORP (IRMD) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. IRADIMED CORPORATION develops, manufactures, and distributes MRI-compatible medical devices, including non-magnetic IV infusion pump systems and patient vital signs monitoring systems. The company operates as a single reportable segment serving hospitals and acute care facilities primarily in the U.S. and internationally.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $20.5 million | $42.4 million |
| Net Income | $5.2 million | $11.0 million |
| Diluted EPS | $0.41 | $0.86 |
| Gross Margin | 74.1% | 75.3% |
| Operating Cash Flow (6mo) | $14.2 million | |
| Cash and Equivalents (Balance) | $59.1 million | |
| Working Capital | $77.6 million | |
| Total Debt | None reported |
Material Changes vs. Prior Period
- Revenue: For the three months ended June 30, 2026, revenue increased slightly by 0.5% ($0.1 million) compared to the prior year. For the six-month period, revenue grew 6.3% ($2.5 million) driven by sales of the new MRidium 3870 IV infusion pump system and increased international sales.
- Profitability: Net income for the quarter decreased 9.6% to $5.2 million from $5.8 million in the prior year quarter. Operating income decreased 5.8% to $6.4 million.
- Margins: Gross margin declined to 74.1% (Q2) and 75.3% (YTD) from 78.2% and 77.1% respectively in the prior year. Management attributed this to initial production inefficiencies associated with new product manufacturing.
- Geography: International revenue surged 69% in the quarter and 33% for the six-month period, offsetting an 8% decline in U.S. revenue for the quarter.
- Expenses: General and administrative expenses decreased 9% in the quarter due to lower legal and professional fees. Sales and marketing expenses increased 6% due to higher commissions on monitor bookings and the new pump system.
Guidance, Outlook, and Risks
- Outlook: Management expects higher revenue for fiscal year 2026 compared to 2025, driven by medical device and disposable sales. However, operating expenses are also expected to be higher due to increased sales, marketing, and regulatory costs.
- Dividends: On July 30, 2026, the Board declared a quarterly cash dividend of $0.20 per share, payable August 28, 2026.
- Tariffs and Geopolitics: The company is evaluating eligibility for refunds on previously paid tariffs following a U.S. Supreme Court ruling in February 2026. While no material adverse impact has been felt yet, ongoing geopolitical conflicts and trade policy changes remain a risk to supply chains and costs.
- Regulatory Risks: The company relies on FDA 510(k) clearances. Delays or denials in regulatory approvals for new products or renewals for existing products could materially impact operations.
- Supply Chain: The company relies on sole-source suppliers for key components; disruptions could adversely affect the business.
Investor Verification Checklist
- Verify the sustainability of the gross margin compression (currently 74-75%) as new product manufacturing ramps up.
- Monitor the timeline and success of the company's application for tariff refunds following the Supreme Court ruling.
- Assess the continued growth trajectory of international sales, which recently outpaced domestic performance.
- Review the impact of the new MRidium 3870 IV infusion pump system on future revenue mix and profitability.
- Confirm the status of regulatory clearances for any new product candidates mentioned in future filings.